Big Cypress Acquisition today relased its S-4 registration statement with the SEC relating to its proposed business combination with SAB Biotherapeutics. The SPAC had filed a draft statement confidentially last month.
If the deal is approved, SAB plans to list on the Nasdaq following the closing of the transaction. The deal implies an enterprise value for SAB on a post-merger basis of approximately $325 million and is expected to provide the combined company with approximately $118 million of pro forma cash (assuming no redemptions from Big Cypress’ trust).
SAB is a clinical-stage biopharmaceutical company that is developing a novel immunotherapy platform producing targeted, high potency, fully-human polyclonal antibody therapeutics and advancing programs in infectious disease, immune system disorders and oncology. Read more.
